Inhibikase Therapeutics

108 articles about Inhibikase Therapeutics

• Inhibikase Therapeutics Regains Compliance with Nasdaq Listing Requirements

  7/17/2023

  Inhibikase Therapeutics, Inc. announced that it received written notice on July 17, 2023 from the Listing Qualifications Staff of The Nasdaq Stock Market, LLC indicating that Inhibikase Therapeutics has regained full compliance with the minimum bid price requirement of $1.00 per share under Nasdaq Listing Rule 5550, and that Inhibikase is in compliance with all applicable listing standards.

• Inhibikase Therapeutics Announces a 1-for-6 Reverse Stock Split

  6/29/2023

  Inhibikase Therapeutics, Inc. today announced that it will effect a 1-for-6 reverse stock split of its common stock.

• Inhibikase Therapeutics Announces Selection of the Bioequivalent Dose of IkT-001Pro and Provides Update on the '501' Bioequivalence Study

  6/22/2023

  Inhibikase Therapeutics, Inc. today announced that it has selected the bioequivalent dose of IkT-001Pro, the Company's prodrug formulation of imatinib mesylate designed to enhance the safety and efficacy of imatinib (marketed as Gleevec®) in patients with Chronic Myelogenous Leukemia (CML) and provided an update on its '501' bioequivalence study.

• Inhibikase Therapeutics Initiates Medical and Patient Awareness Campaign for its Phase 2 '201' Trial Evaluating IkT-148009 in Parkinson's Disease

  6/21/2023

  Inhibikase Therapeutics, Inc. today announced a physician and patient awareness campaign for its Phase 2 '201' program evaluating IkT-148009 as a potentially disease-modifying treatment of Parkinson's disease.

• Inhibikase Therapeutics to Present at the LD Micro Invitational XIII

  5/30/2023

  Inhibikase Therapeutics, Inc.  today announced that Dr. Milton Werner Ph.D., President & Chief Executive Officer of Inhibikase, will deliver a presentation at the LD Micro Invitational XIII Conference being held on June 6-8, 2023, in Los Angeles, California.

• Inhibikase Therapeutics Announces Dosing of First Patient in its Phase 2 '201' Clinical Trial of IkT-148009 to Treat Parkinson's Disease

  5/16/2023

  Inhibikase Therapeutics, Inc. today announced that the first patient has been dosed in its Phase 2 '201' trial evaluating IkT-148009, the Company's novel Abelson Tyrosine Kinase, or c-Abl, inhibitor for the treatment of Parkinson's disease.

• Inhibikase Therapeutics Reports First Quarter Financial Results and Highlights Recent Period Activity

  5/15/2023

  Inhibikase Therapeutics, Inc. today reported financial results for the first quarter ended March 31, 2023 and highlighted recent developments.

• Inhibikase Therapeutics to Report First Quarter Financial Results on May 15, 2023

  5/8/2023

  Inhibikase Therapeutics, Inc. today announced that it will report financial results for the first quarter ended March 31, 2023, on Monday, May 15, 2023, after the close of U.S. markets.

• Inhibikase Therapeutics to Present at the Sidoti Micro-Cap Virtual Conference

  5/4/2023

  Inhibikase Therapeutics, Inc. today announced that Dr. Milton Werner, Ph.D., President & Chief Executive Officer of Inhibikase, will deliver a presentation at the Sidoti Micro-Cap Virtual Conference being held on May 10-11, 2023.

• Inhibikase Therapeutics Provides Safety and Functional Update on its Phase 1/1b 101 Trial and its Phase 2 IkT-148009 201 Trial in Parkinson's Disease

  4/26/2023

  Inhibikase Therapeutics, Inc. today reported updates in the design and execution of its Phase 2 '201' program with IkT-148009 to treat Parkinson's disease.

• Inhibikase Therapeutics to Present at the 2023 Planet MicroCap Showcase

  4/21/2023

  Inhibikase Therapeutics, Inc. today announced that Dr. Milton Werner, Ph.D., President & Chief Executive Officer of Inhibikase, and Joseph Frattaroli, Chief Financial Officer of Inhibikase, will deliver a presentation at the 2023 Planet MicroCap Showcase being held on April 25-27, 2023 in Las Vegas, Nevada.

• Inhibikase Therapeutics Reports Full Year 2022 Financial Results and Highlights Recent Period Activity

  3/31/2023

  Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company) today reported financial results for the full year ended December 31, 2022 and highlighted recent developments.

• Inhibikase Therapeutics to Report Fourth Quarter and Full-Year 2022 Financial Results on March 31, 2023

  3/23/2023

  Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company") today announced that it will report financial results for the fourth quarter and full-year ended December 31, 2022 on Friday, March 31, 2023, after the close of U.S. markets.

• Inhibikase Therapeutics to Present at the International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders

  3/21/2023

  Inhibikase Therapeutics, Inc. today announced that Milton Werner will present at the International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders (AD/PD™), being held in Gothenburg, Sweden, and virtually, from March 28-April 1, 2023.

• Inhibikase Therapeutics to Host Virtual R&D Event on March 22, 2023

  3/16/2023

  Inhibikase Therapeutics, Inc. today announced that it will host a virtual R&D Event on Wednesday, March 22, 2023 at 11:00 am ET.

• Inhibikase Therapeutics Provides Interim Update on the '501' Bioequivalence Study of IkT-001Pro

  3/15/2023

  Inhibikase Therapeutics, Inc. provided an interim update from the dose escalation portion of its '501' bioequivalence study of IkT-001Pro, the Company's prodrug formulation of imatinib mesylate designed to enhance the safety and efficacy of imatinib in patients with Chronic Myelogenous Leukemia.

• Inhibikase Therapeutics Announces FDA has Lifted the Full Clinical Hold on IkT-148009 in Multiple System Atrophy

  3/8/2023

  Inhibikase Therapeutics, Inc. today announced the U.S. Food and Drug Administration ("FDA" or "Agency") has lifted the full Clinical Hold on IkT-148009, the Company's c-Abl inhibitor, in Multiple System Atrophy (MSA) allowing the Company to proceed with its plans for a future Phase 2 clinical trial in MSA.

• Inhibikase Therapeutics to Present at the 11th Annual Alzheimer's & Parkinson's Drug Development Summit

  2/15/2023

  Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company") today announced that Milton Werner, Ph.D., President and Chief Executive Officer of Inhibikase, will present at the 11th Annual Alzheimer's & Parkinson's Drug Development Summit.

• Inhibikase Therapeutics Announces Closing of $10 Million Concurrent Registered Direct Offering and Private Placement Priced At a Premium to Market Under Nasdaq Rules

  1/27/2023

  Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company") today announced that it has closed its previously announced registered direct offering for the issuance and sale of 6,744,187 of its shares of common stock (or common stock equivalents) at a purchase price of $0.86 per share (or common stock equivalent).

• Inhibikase Therapeutics Announces Publication Demonstrating Potential for c-Abl as a Key Therapeutic Target in Parkinson's Disease and Related Disorders

  1/25/2023

  Inhibikase Therapeutics, Inc. today announced the publication of studies describing the potential of IkT-148009 as a disease-modifying therapy for Parkinson's disease and related disorders.